235 related articles for article (PubMed ID: 10344709)
21. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.
Corbet A; Bucciarelli R; Goldman S; Mammel M; Wold D; Long W
J Pediatr; 1991 Feb; 118(2):277-84. PubMed ID: 1993961
[TBL] [Abstract][Full Text] [Related]
22. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
Bahadue FL; Soll R
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD001456. PubMed ID: 23152207
[TBL] [Abstract][Full Text] [Related]
23. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation.
Malathi I; Ng KC
Ann Acad Med Singap; 1995 Nov; 24(6):781-4. PubMed ID: 8838980
[TBL] [Abstract][Full Text] [Related]
24. Exosurf versus Survanta surfactant preparations: proportional-hazards regression analysis of time to successful extubation and discontinuation of oxygen therapy.
Arnold C; Adams E; Torres E; Sidebottom R
J Perinatol; 1996; 16(1):9-14. PubMed ID: 8869533
[TBL] [Abstract][Full Text] [Related]
25. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
[TBL] [Abstract][Full Text] [Related]
26. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
[TBL] [Abstract][Full Text] [Related]
27. [Natural and synthetic surfactant in the treatment of neonatal respiratory distress syndrome].
Bratlid D; Farstad T
Tidsskr Nor Laegeforen; 1994 Jan; 114(1):33-6. PubMed ID: 8296279
[TBL] [Abstract][Full Text] [Related]
28. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I.
Stevenson D; Walther F; Long W; Sell M; Pauly T; Gong A; Easa D; Pramanik A; LeBlanc M; Anday E
J Pediatr; 1992 Feb; 120(2 Pt 2):S3-12. PubMed ID: 1735849
[TBL] [Abstract][Full Text] [Related]
29. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment.
Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO
Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting the neonatal response to artificial surfactant.
Skelton R; Jeffery HE
J Paediatr Child Health; 1996 Jun; 32(3):236-41. PubMed ID: 8827542
[TBL] [Abstract][Full Text] [Related]
31. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Canadian Exosurf Neonatal Follow-Up Group.
Casiro O; Bingham W; MacMurray B; Whitfield M; Saigal S; Vincer M; Long W
J Pediatr; 1995 May; 126(5 Pt 2):S53-60. PubMed ID: 7745512
[TBL] [Abstract][Full Text] [Related]
32. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome.
Billman D; Nicks J; Schumacher R
Pediatr Pulmonol; 1994 Nov; 18(5):279-83. PubMed ID: 7898965
[TBL] [Abstract][Full Text] [Related]
33. Comparative randomized study: administration of natural and synthetic surfactant to premature newborns with respiratory distress syndrome.
Giannakopoulou C; Hatzidaki E; Korakaki E; Christodoulaki M; Margari KM; Mamoulakis D
Pediatr Int; 2002 Apr; 44(2):117-21. PubMed ID: 11896865
[TBL] [Abstract][Full Text] [Related]
34. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
[TBL] [Abstract][Full Text] [Related]
35. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.
Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087
[TBL] [Abstract][Full Text] [Related]
36. Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant.
Corbet AJ; Long WA; Murphy DJ; Garcia-Prats JA; Lombardy LR; Wold DE
J Paediatr Child Health; 1991 Aug; 27(4):245-9. PubMed ID: 1958425
[TBL] [Abstract][Full Text] [Related]
37. Effects of two rescue doses of synthetic surfactant in 344 infants with respiratory distress syndrome weighing 750 to 1249 grams: a double-blind, placebo-controlled multicenter Canadian trial. Canadian Exosurf Neonatal Study Group.
McMillan D; Chernick V; Finer N; Schiff D; Bard H; Watts J; Krzeski R; Long W
J Pediatr; 1995 May; 126(5 Pt 2):S90-8. PubMed ID: 7745517
[TBL] [Abstract][Full Text] [Related]
38. Surfactant replacement therapy improves ventilation inhomogeneity in infants with respiratory distress syndrome.
Sandberg KL; Lindstrom DP; Sjöqvist BA; Parker RA; Cotton RB
Pediatr Pulmonol; 1997 Nov; 24(5):337-43. PubMed ID: 9407567
[TBL] [Abstract][Full Text] [Related]
39. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I.
Sell M; Cotton R; Hirata T; Guthrie R; LeBlanc M; Mammel M; Long W
J Pediatr; 1995 May; 126(5 Pt 2):S20-5. PubMed ID: 7745507
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome.
Lam BC; Ng YK; Wong KY
Pediatr Pulmonol; 2005 Jan; 39(1):64-9. PubMed ID: 15558604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
